Spots Global Cancer Trial Database for Approaches to Identify Early Biomarkers and Pathogenesis of Anthracycline Cardiotoxicity

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Approaches to Identify Early Biomarkers and Pathogenesis of Anthracycline Cardiotoxicity

Official Title: Integrated Basis and Translational Approaches to Identify Early Biomarkers and Pathogenesis of Anthracycline Cardiotoxicity

Study ID: NCT04036045

Conditions

Childhood Cancer

Interventions

Cardiac MRI

Echocardiogram

Blood Draw

Study Description

Brief Summary: Early microRNAs (miRs) and Cardiac Magnetic Resonance (CMR)-derived strain analysis and detection of genes contributing to Anthracycline-Induced Cardiotoxicity (AIC) sensitivity and resistance will identify pediatric cancer patients most and least likely to develop AIC.

Detailed Description: Plan is to enroll 110 children and adults (≥9 years old) newly diagnosed at CCMC and Nationwide Children's Hospital (55 per institution) who will receive anthracyclines as part of their chemotherapy regimen. The duration of study participation will be approximately a year. Patients will have a total of four study visits: Baseline 1 week after patient's anthracycline cumulative dose hits between 60 and 100 mg/m2 After the patient has completed maximal therapy One year after completion of anthracycline treatments Study tasks for all four visits will be: Collection of clinical data Blood draw for micro RNA and Biomarkers Cardiac MRI Echocardiogram One time blood draw for genetics